Skip to content
OpenCapital
Get started

Dolby Laboratories, Inc. DLB Accounts receivable from patent administration program licensees

Other financials

Income statement

See full
Revenue$395.6M+7.1%
Gross profit$350.9M+5.1%
Operating income$112.9M+4.8%
Net income$94.9M+3.4%
EPS (diluted)$0.99+5.3%

Balance sheet

See full
Cash & equivalents$673.8M-10.2%
Total debt$49.7M+22.9%
Total equity$2.6B+1.7%
Total assets$3.2B+0.6%

Cash flow

See full
Operating cash flow$92.5M-47.1%
CapEx$9.1M+31.4%
Free cash flow$83.4M-50.3%

Valuation

See full
Market cap$4.95B-25.9%

Profitability

See full
Gross margin87.4%-1.5pp
Operating margin18.5%-2.0pp
Net margin17.9%-1.6pp
FCF margin22.1%-7.5pp

Returns & leverage

See full
Return on equity9.4%-0.9pp
Debt / equity0×0.0×
Current ratio3×-0.1×

Where this comes from

Reported directly by Dolby Laboratories, Inc. in its filing.

Tagged under the XBRL concept dlb:AccountsReceivableRelatedToPatentAdministrationProgram.

The official record: Dolby Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Dolby Laboratories, Inc.'s accounts receivable from patent administration program licensees?
Dolby Laboratories, Inc. (DLB) reported accounts receivable from patent administration program licensees of $191M in Q1 2026.
How has Dolby Laboratories, Inc.'s accounts receivable from patent administration program licensees changed year-over-year?
Dolby Laboratories, Inc.'s accounts receivable from patent administration program licensees increased by 34.5% year-over-year, from $141.98M to $191M.
What is the long-term trend for Dolby Laboratories, Inc.'s accounts receivable from patent administration program licensees?
Over 5 years (2020 to 2025), Dolby Laboratories, Inc.'s accounts receivable from patent administration program licensees has grown at a 25.6% compound annual growth rate (CAGR), from $48.63M to $152.1M.